Policy & Regulation
COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial
19 October 2021 - - French biotechnology company Valneva SE has reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using US-based biopharmaceutical company Dynavax Technologies Corp's (NASDAQ: DVAX) CpG 1018 adjuvant, Dynavax said.

Valneva reported the following data from their Phase 3 COV-COMPARE trial in a press release issued October 18, 2021.

The trial met its co-primary endpoints: VLA2001 demonstrated superiority against AZD1222 (ChAdOx1-S), in terms of geometric mean titer for neutralization antibodies (GMT ratio=1.39, p


Related Headlines